A Novel Approach to Dual-Acting Thromboxane Receptor Antagonist/Synthase Inhibitors Based on the Link of 1,3-Dioxane-Thromboxane Receptor Antagonists and -Thromboxane Synthase Inhibitors
摘要:
A new class of dual-acting racemic thromboxane receptor antagonist/thromboxane synthase inhibitors is reported, based on the novel approach of linking the known thromboxane synthase inhibitors (TXSI) dazoxiben (2) or isbogrel(11) (separately) to thromboxane receptor antagonists (TXRA) from the 1,3-dioxane series, such as ICI 192605 (10). Dual activity was observed in vitro with inhibition of human microsomal thromboxane synthase in the range IC50 = 0.01-1.0 mu M and receptor antagonist activity by inhibition of U46619-induced human platelet aggregation in the range pA(2) = 5.5-7.0. The in vitro results also showed that very large groups could be tolerated at the selected substitution positions of the TXRA and TXSI components. Oral activity was observed in ex vivo tests in both rats and dogs at a dose of 10 mg/kg. Thus, (E)-7-[4-[[4-[(2SR,4SR,5RS)-5-[(Z)-5-carboxypent-2-enyl]-4-(2-hydroxyphenyl)-1,3-dioxan-2-yl]benzyl]oxy]phenyl]-7-(3-pyridyl)hept-6-enoic acid (110) was both an antagonist (pA(2) = 6.7) and a synthase inhibitor (IC50 = 0.02 mu M). On oral dosing (10 mg/kg) to rats and dogs, 110 showed significant TXRA activity [concentration ratio >64 (rat, 3 h) and >59 +/- 11.3 (dog, 2 h) vs ex vivo U46619-induced platelet aggregation]. Inhibition of thromboxane synthase at the respective time points in these experiments was 81 +/- 4.4% (rat) and 69 +/- 4.8% (dog).
Rapid Cyclic Acetal and Cyclic Ketal Synthesis Assisted by a Rotary Evaporator
作者:Fuyao Jiang、Yinzhe Chen、Qian Zhang、Weiding Wang
DOI:10.1055/a-2293-3243
日期:2024.11
Herein, we present a rapid and efficient method for synthesizing cyclicacetals and ketals utilizing a rotary evaporator. Unlike the conventional Dean–Stark dehydration process, which typically demands extended reaction times and copious amounts of organic solvents, our approach affords the synthesis of cyclicacetals and ketals with varying ring sizes in 30 min while using minimal quantities of dimethyl
TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES
申请人:AGOURON PHARMACEUTICALS, INC.
公开号:EP1208104A2
公开(公告)日:2002-05-29
US6548494B1
申请人:——
公开号:US6548494B1
公开(公告)日:2003-04-15
[EN] TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES<br/>[FR] INHIBITEURS TRICYCLIQUES DE POLY(ADP-RIBOSE) POLYMERASES
申请人:AGOURON PHARMA
公开号:WO2001016136A2
公开(公告)日:2001-03-08
Compounds of the formula (I) are poly(ADP-ribosyl)transferase inhibitors. Such compounds are useful as therapeutics in treating cancers and in ameliorating the effects of stroke, head trauma, and neurodegenerative disease.